# China NMPA Drug Inspection - Anhui Zhongmeitang Traditional Chinese Medicine Pieces Co., Ltd. - Fangji

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/anhui-zhongmeitang-traditional-chinese-medicine-pieces-co-ltd/30286d23-8af4-4437-bbf2-852280c02aca/
Source feed: China

> China NMPA drug inspection for Anhui Zhongmeitang Traditional Chinese Medicine Pieces Co., Ltd. published June 08, 2018. Drug: Fangji. The Heilongjiang Provincial Food and Drug Administration (FDA) issued an announcement on June 8, 2018, detailing finding

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from the Heilongjiang Provincial Food and Drug Administration regarding 9 batches of substandard drugs (Issue No. 6, 2018)
- Company Name: Anhui Zhongmeitang Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2018-06-08
- Drug Name: Fangji
- Inspection Finding: The non-compliant items were appearance and identification, and upon verification, it was confirmed that the product was not manufactured by the labeling company.
- Action Taken: The relevant food and drug administration departments have taken control measures such as sealing and seizing, and have required the sampled units to stop selling and using the batch of products; they have also initiated investigations into illegal acts of selling and using substandard drugs, and will deal with them in accordance with the law, transferring cases suspected of being criminal to the public security departments in accordance with the law.
- Summary: The Heilongjiang Provincial Food and Drug Administration (FDA) issued an announcement on June 8, 2018, detailing findings from tests conducted by five institutions on nine batches of substandard drugs. Key issues involved multiple pharmaceutical companies and their products. Henan Jinhongtang Pharmaceutical Co., Ltd. (Shujin Huoxue Tablets), Tianjin Jinyao Group Hubei Tianyao Pharmaceutical Co., Ltd. (Dexamethasone Sodium Phosphate Injection), and Heilongjiang Xiangtai Traditional Chinese Medicine Pieces Co., Ltd. (Ziziphus Jujuba Seed (fried)) had products failing general inspection and appearance criteria. A further six batches, including Poria cocos from Bozhou Traditional Chinese Medicine Pieces Factory and Compound Glycyrrhiza Tablets from Guangxi Guilin Nanfang Pharmaceutical Co., Ltd., failed appearance and identification tests. Critically, these six batches were confirmed not to have been produced by their labeled manufacturers, indicating significant mislabeling or potential counterfeiting. Pursuant to Articles 73, 74, and 75 of the *Drug Administration Law of the People's Republic of China*, regulatory bodies mandated immediate actions. Local food and drug administrations were instructed to implement control measures such as sealing and seizing affected products, requiring units to cease sales and usage. Furthermore, departments must investigate and prosecute illegal activities, referring criminal cases to public security departments. Resolution outcomes must be publicized within three months and reported to the Provincial Bureau, reinforcing stringent oversight on drug quality and safety.

Company: https://www.globalkeysolutions.net/companies/anhui-zhongmeitang-traditional-chinese-medicine-pieces-co-ltd/4a1dc5e0-b023-4d15-8511-24385790ddb3/